These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 21295125)

  • 1. The impact of material attributes and process parameters on the micronisation of lactose monohydrate.
    Shariare MH; de Matas M; York P; Shao Q
    Int J Pharm; 2011 Apr; 408(1-2):58-66. PubMed ID: 21295125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dry powder inhalers: mechanistic evaluation of lactose formulations containing salbutamol sulphate.
    Kaialy W; Ticehurst M; Nokhodchi A
    Int J Pharm; 2012 Feb; 423(2):184-94. PubMed ID: 22197772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of crystal form of ipratropium bromide on micronisation and aerosolisation behaviour in dry powder inhaler formulations.
    Shur J; Kubavat HA; Ruecroft G; Hipkiss D; Price R
    J Pharm Pharmacol; 2012 Sep; 64(9):1326-36. PubMed ID: 22881444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of mechanical activation on the physical stability of salbutamol sulphate.
    Brodka-Pfeiffer K; Langguth P; Grass P; Häusler H
    Eur J Pharm Biopharm; 2003 Nov; 56(3):393-400. PubMed ID: 14602182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Form conversion of anhydrous lactose during wet granulation and its effect on compactibility.
    Shah KR; Hussain MA; Hubert M; Farag Badawy SI
    Int J Pharm; 2008 Jun; 357(1-2):228-34. PubMed ID: 18374527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing the re-crystallization behaviour of amorphous lactose using the RH-perfusion cell.
    Timmermann IL; Steckel H; Trunk M
    Eur J Pharm Biopharm; 2006 Aug; 64(1):107-14. PubMed ID: 16527465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physicochemical and in vitro deposition properties of salbutamol sulphate/ipratropium bromide and salbutamol sulphate/excipient spray dried mixtures for use in dry powder inhalers.
    Corrigan DO; Corrigan OI; Healy AM
    Int J Pharm; 2006 Sep; 322(1-2):22-30. PubMed ID: 16815654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preparation and Evaluation of Surface Modified Lactose Particles for Improved Performance of Fluticasone Propionate Dry Powder Inhaler.
    Singh DJ; Jain RR; Soni PS; Abdul S; Darshana H; Gaikwad RV; Menon MD
    J Aerosol Med Pulm Drug Deliv; 2015 Aug; 28(4):254-67. PubMed ID: 25517187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The surface characterisation and comparison of two potential sub-micron, sugar bulking excipients for use in low-dose, suspension formulations in metered dose inhalers.
    James J; Crean B; Davies M; Toon R; Jinks P; Roberts CJ
    Int J Pharm; 2008 Sep; 361(1-2):209-21. PubMed ID: 18577435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of nanomechanical crystal properties on the comminution process of particulate solids in spiral jet mills.
    Zügner S; Marquardt K; Zimmermann I
    Eur J Pharm Biopharm; 2006 Feb; 62(2):194-201. PubMed ID: 16202574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effective modification of particle surface properties using ultrasonic water mist.
    Genina N; Räikkönen H; Heinämäki J; Antikainen O; Siiriä S; Veski P; Yliruusi J
    AAPS PharmSciTech; 2009; 10(1):282-8. PubMed ID: 19288203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of primary crystallisation conditions on the mechanical and interfacial properties of micronised budesonide for dry powder inhalation.
    Kubavat HA; Shur J; Ruecroft G; Hipkiss D; Price R
    Int J Pharm; 2012 Jul; 430(1-2):26-33. PubMed ID: 22449413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved aerosolization performance of salbutamol sulfate formulated with lactose crystallized from binary mixtures of ethanol-acetone.
    Kaialy W; Ticehurst MD; Murphy J; Nokhodchi A
    J Pharm Sci; 2011 Jul; 100(7):2665-84. PubMed ID: 21268026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of ageing, grinding and preheating on the thermal behaviour of alpha-lactose monohydrate.
    Garnier S; Petit S; Mallet F; Petit MN; Lemarchand D; Coste S; Lefebvre J; Coquerel G
    Int J Pharm; 2008 Sep; 361(1-2):131-40. PubMed ID: 18617338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterising surface energy of pharmaceutical powders by inverse gas chromatography at finite dilution.
    Das SC; Stewart PJ
    J Pharm Pharmacol; 2012 Sep; 64(9):1337-48. PubMed ID: 22881445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gas-pressurized dispersive powder flow tester for low volume sample characterization.
    Majid AM; Wong TW
    Int J Pharm; 2013 May; 448(1):150-8. PubMed ID: 23506957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of the lactose grade within dry powder formulations of fluticasone propionate and terbutaline sulphate.
    Le VN; Bierend H; Robins E; Steckel H; Flament MP
    Int J Pharm; 2012 Jan; 422(1-2):75-82. PubMed ID: 22036653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The influence of carrier and drug morphology on drug delivery from dry powder formulations.
    Larhrib H; Martin GP; Marriott C; Prime D
    Int J Pharm; 2003 May; 257(1-2):283-96. PubMed ID: 12711183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of crystallisation conditions and feedstock morphology on the aerosolization performance of micronised salbutamol sulphate.
    Shariare MH; de Matas M; York P
    Int J Pharm; 2011 Aug; 415(1-2):62-72. PubMed ID: 21683128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Understanding the effect of lactose particle size on the properties of DPI formulations using experimental design.
    Guenette E; Barrett A; Kraus D; Brody R; Harding L; Magee G
    Int J Pharm; 2009 Oct; 380(1-2):80-8. PubMed ID: 19596428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.